shouldiuse.io

Categories

VERDICT

Fierce Biotech Review

Depends

Should I use Fierce Biotech?

Biotech and pharma trade news publication, a division of Forge (sister site: Fierce Pharma) - fiercebiotech.com

· 4 days ago

Fierce Biotech is a free trade publication covering biotech trials, deals, layoffs, and startup awards. Read it for industry awareness; buy a data platform if you need structured intelligence.

Confidence

Medium. Based on 100+ public sources; many pages are Fierce Biotech's own site.

Ratings

  • Value for money
  • Ease of useNo evidence in sources
  • Feature depth
  • Support qualityNo evidence in sources
  • Security posture

Pricing

Guess: $0

News access

ModelNot disclosed
Monthly feesNot disclosed
HardwareNot disclosed
Free tierYes

Best for

  • Biotech industry watchers
  • BD and VC deal spotters
  • Comms teams tracking competitor news
  • Startup scouting via Fierce 15

Not for

  • Teams shopping for software
  • Researchers needing verified primary data
  • Buyers wanting structured trial or patent data
  • Readers who dislike sponsored content

Gotchas - check before you buy

medium

Gated downloads require contact info; expect vendor follow-up.

medium

Sponsored content sits beside journalism; check labels before trusting a piece.

low

Fierce 15 and trackers are editorial picks, not diligence-grade data.

Pros and cons

Pros

  • Daily coverage of trials, funding, layoffs, lawsuits, and FDA moves.
  • Runs Fierce 15 awards since 2011, spotlighting promising startups.
  • Maintains live 2026 fundraising and layoff trackers.
  • Gridinsoft gives the site an excellent trust score.
  • Part of a network with Fierce Pharma and Fierce Medtech.

Cons

  • Publication, not software; no integrations or workflows.
  • Resources section mixes vendor-sponsored white papers with journalism.
  • Some readers switch to DrugPatentWatch for patent data.
  • Webinars and buyer guides capture your contact details.

Sources & method

- 11 sources - No known vulnerabilities found in the sources reviewed.

official x4review x4news x3

Key stats

  • Value for money: 4/5

    Rating

  • Guess: $0

    Starting price

  • 11

    Sources

  • Analyzed

  • Value for money: 4/5. Guess: free to read; sponsored content funds it
  • Ease of use. No evidence in sources
  • Feature depth: 3/5. News, trackers, Fierce 15, gated webinars
  • Support quality. No evidence in sources
  • Security posture: 4/5. Gridinsoft reports an excellent trust score
  • 2005 Publishing since Earliest article in evidence
  • Excellent Trust score Gridinsoft site scanner
  • 5,241 Facebook followers Fierce Biotech page
  • Fierce 15 since 2011 Signature features Plus 2026 funding and layoff trackers

Pricing

News access

Guess: $0

  • Biotech and pharma news
  • Trackers and award lists
  • Gated webinars and white papers

Security

No known vulnerabilities found in the sources reviewed.

What users say

Reddit users name FierceBiotech and FiercePharma as go-to biotech news outlets, often alongside Endpoints News.

Full analysis

Based on 100+ public sources; many pages are Fierce Biotech's own site.

Free biotech trade news site, not software. Good for industry tracking; no data tools inside.

Methodology

Based on 100+ public sources; many pages are Fierce Biotech's own site.

Read how a report is made.

Sources

  1. official
  2. official
  3. official
  4. official
  5. news
  6. review
  7. review
  8. review
  9. review
  10. news
  11. news

Add this review to your site

This check for Fierce Biotech says Depends.

Put the badge on your site.

Visitors see the independent review.

The link points here, and search engines follow it.

This is the badge visitors see on your site.

Paste one snippet. Keep the link as it is. A nofollow tag stops search engines from following it.

Rate this review

Anonymous. You can change your vote.

Loading votes…

Comments

One queue. No nested comments. Give a display name first. Limit: 200 words per comment and 7 comments per day. You can edit or delete yours.

Save a name to write a comment.

0 / 200 words

No comments yet.